Your session is about to expire
← Back to Search
Spatial Localization and Mapping (SLAM) and object recognition technology
Navigation System for Vision Impairment (SLAM Trial)
N/A
Recruiting
Led By Seth Billings, Ph.D.
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subject must be an adult (at least 18 years of age)
Subject is able to walk unassisted
Must not have
Subject does not speak English
Subject is unwilling or unable to travel to testing facility for at least 3 days of testing within a one-week timeframe
Timeline
Screening 3 weeks
Treatment Varies
Follow Up trial duration: estimated at up to one minute.
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new technology that helps blind people navigate by creating a map of their surroundings and providing visual and sound cues. It targets legally blind individuals using the Argus II retinal prosthesis. The system helps users understand where they are and what objects are around them. The Argus II retinal prosthesis system has been developed to restore some vision to patients blind due to retinitis pigmentosa or outer retinal degeneration.
Who is the study for?
This trial is for adults with vision impairments or specific conditions like Retinitis Pigmentosa who can follow instructions, give feedback, and speak English. They should be able to participate in testing for up to 6 hours a day over several days, walk unassisted, have good cognitive abilities, and visual acuity of at least 20/40 when corrected.
What is being tested?
The study tests a navigation system that uses Spatial Localization and Mapping (SLAM) technology along with object recognition to help users of visual prostheses navigate their environment. It will involve both sighted individuals using VR headsets and actual prosthesis users.
What are the potential side effects?
Since this trial involves non-invasive technology rather than medication or surgery, traditional side effects are not expected. Participants may experience discomfort from prolonged use of VR headsets or fatigue from extensive testing sessions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am at least 18 years old.
Select...
I can walk by myself without help.
Select...
I am at least 18 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not speak English.
Select...
I cannot or will not go to the testing facility for 3 days within a week.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Accuracy as assessed as ratio of target identification success to total trials
Success in psychophysical judgments
Trial Time as assessed by mean time duration to identify target
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Navigation system for users of a visual prosthesisExperimental Treatment1 Intervention
This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition. The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis. Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems. Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for visual impairment, particularly those involving retinal prosthesis, include technologies like Spatial Localization and Mapping (SLAM) and object recognition. These technologies work by constructing a detailed map of the user's environment and accurately locating the user within that map.
This is achieved through the integration of visual and auditory feedback, which helps users navigate their surroundings more effectively. For patients with visual impairment, these advancements are crucial as they significantly enhance spatial awareness and mobility, thereby improving their overall quality of life and independence.
Interventions Addressing Vision, Visual-perceptual Impairments Following Acquired Brain Injury: A Cross-sectional Survey.A Review of Cochrane Systematic Reviews of Interventions Relevant to Orthoptic Practice.
Interventions Addressing Vision, Visual-perceptual Impairments Following Acquired Brain Injury: A Cross-sectional Survey.A Review of Cochrane Systematic Reviews of Interventions Relevant to Orthoptic Practice.
Find a Location
Who is running the clinical trial?
Johns Hopkins UniversityLead Sponsor
2,323 Previous Clinical Trials
14,874,272 Total Patients Enrolled
9 Trials studying Retinitis Pigmentosa
876 Patients Enrolled for Retinitis Pigmentosa
Carnegie Mellon UniversityOTHER
77 Previous Clinical Trials
539,867 Total Patients Enrolled
National Eye Institute (NEI)NIH
554 Previous Clinical Trials
1,407,304 Total Patients Enrolled
24 Trials studying Retinitis Pigmentosa
14,530 Patients Enrolled for Retinitis Pigmentosa
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I can follow instructions and communicate my thoughts clearly.I am willing to undergo testing for 4-6 hours a day over 3-5 days.I do not speak English.You can see clearly with glasses or contacts, at least as well as someone with 20/40 vision.I am at least 18 years old.I can walk by myself without help.You speak English.I cannot or will not go to the testing facility for 3 days within a week.I understand the study information and can give my consent in writing.I am willing to undergo tests related to my senses and perception for up to 4-6 hours a day over 3-5 days.I can follow instructions and communicate my thoughts clearly.I am at least 18 years old.I understand the study information and can give my written consent.You have good eyesight with or without glasses.
Research Study Groups:
This trial has the following groups:- Group 1: Navigation system for users of a visual prosthesis
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Retinitis Pigmentosa Patient Testimony for trial: Trial Name: NCT04359108 — N/A
Share this study with friends
Copy Link
Messenger